GSTM1 and kidney disorder: The following year, the 2012 guidelines of the Kidney Disease Improving Global Outcomes (Kidney Disease Improving Global Outcomes [KDIGO], 2012) advised that for adult CKD patients with Hb concentration ≥10.0 g/dL, ESA therapy should not be initiated.